Anti-Influenza Hyperimmune Intravenous Immunoglobulin, Clinical Outcome Study, (INSIGHT 006: FLU-IVIG)

Regents of the University of Minnesota0 个研究点目标入组 329 人开始时间: 2015年3月3日最近更新: 2019年12月10日

适应症

试验速览

暂无简介。

•1. Signed informed consent
•2. Age ? 18 years of age
•3. Locally determined positive influenza test (by PCR or other nucleic acid testing, or
•by rapid Ag) from a specimen obtained within 2 days prior to randomization
•4. Onset of illness no more than 7 days before randomization, defined as when the
•patient first experienced at least one respiratory symptom or fever
•5. Hospitalized (or in observation unit) for influenza, with anticipated hospitalization for
•more than 24 hours. Criteria for hospitalization will be up to the individual treating
•6. For women of child-bearing potential: willingness to abstain from sexual intercourse
•or use at least 1 form of hormonal or barrier contraception through Day 28 of the
•7. Willingness to have blood and respiratory samples obtained and stored
•8. NEW score ? 2 at screening
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 250
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 70

•1. Women who are pregnant or breast-feeding
•2. Strong clinical evidence (in the judgment of the site investigator) that the etiology of illness is primarily bacterial in origin
•3. Prior treatment with any investigational drug therapy within 30 days prior to screening
•4. History of allergic reaction to blood or plasma products (as judged by the site investigator)
•5. Known IgA deficiency
•6. A pre-existing condition or use of a medication that, in the opinion of the site investigator, may place the individual at a substantially increased risk of thrombosis (e.g., cryoglobulinemia, severe refractory hypertriglyceridemia, or clinically
•significant monoclonal gammopathy)
•7. Presence of any pre-existing illness that, in the opinion of the site investigator, would place the individual at an unreasonably increased risk through participation in this study
•8. Patients who, in the judgment of the site investigator, will be unlikely to comply with the requirements of this protocol
•9. Medical conditions for which receipt of a 500 mL volume of intravenous fluid may be dangerous to the patient (e.g., decompensated congestive heart failure)
•10. Receiving extracorporeal membrane oxygenation (ECMO)
•11. Suspicion that infection is due to an influenza strain or subtype other than A(H1N1)pdm09, H3N2, or influenza B (e.g., H5N1, H7N9)

发起方